[Antibioprophylaxis failure with BCG therapy for bladder neoplasia].

Rev Mal Respir

Service de pneumologie et explorations fonctionnelles respiratoires, CHRU de Tours, Tours, France; UMR 1100, université François-Rabelais, Tours, France; Inserm, centre d'étude des pathologies respiratoires, UMR 1100/EA6305, Tours, France. Electronic address:

Published: December 2024

Introduction: BCG therapy is the standard treatment for bladder tumors that do not infiltrate smooth muscle. Fluoroquinolones for antibiotic prophylaxis are recommended to lessen the risk of BCG infection (BCGitis) with respiratory involvement.

Case Report: This study describes five cases of BCGitis in males, with a median age of 71years [range: 66-77years] having undergone ofloxacin prophylaxis during their BCG therapy for a non-invasive bladder tumor (grade pT1a). Among these patients, four experienced fever within eight hours of the last instillation, as well as respiratory symptoms such as dyspnea and cough. Three of them exhibited substantial weight loss over the course of one month. Chest scans consistently revealed miliary patterns. While only in one patient was BCG identification confirmed, typical clinical and CT presentations prompted the initiation of treatment, predominantly employing a combination of isoniazid, rifampicin, and ethambutol in four patients, and isoniazid and rifampicin in the fifth. Treatment duration ranged from six to nine months. One-year follow-up indicated a favourable outcome for all patients.

Conclusions: This study shows that ofloxacin prophylaxis may in some cases fail to prevent iatrogenic BCGitis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmr.2024.11.004DOI Listing

Publication Analysis

Top Keywords

bcg therapy
12
ofloxacin prophylaxis
8
isoniazid rifampicin
8
bcg
5
[antibioprophylaxis failure
4
failure bcg
4
therapy bladder
4
bladder neoplasia]
4
neoplasia] introduction
4
introduction bcg
4

Similar Publications

Speed of innovation: how quickly are different therapeutic areas adopting paradigm-shifting drugs?

Drug Discov Today

December 2024

Boston Consulting Group, 80 Charlotte Street, London, W1T 4DF, UK. Electronic address:

The past decades have seen breakthroughs in drug discovery that have revolutionized the treatment of many diseases. These paradigm-shifting treatments are often novel targeted therapies, directed at new areas of biology. To better understand these paradigm shifts, we conducted an analysis of the adoption of 25 drug classes from five major therapeutic areas (TAs).

View Article and Find Full Text PDF

Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics.

Biochem Biophys Res Commun

December 2024

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address:

Melanoma, recognized as one of the most aggressive forms of skin cancer, continues to show a steady rise in global incidence. While Bacillus Calmette-Guérin (BCG) has been identified as a potential intralesional therapy for melanoma, its therapeutic efficacy remains suboptimal. This study introduces a novel thermosensitive hydrogel formulated with BCG lysates and either OVA peptide or tumor cell lysates (PPP-BCG-OVA/TL).

View Article and Find Full Text PDF

Background And Objective: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives.

View Article and Find Full Text PDF

Purpose: This study aimed to comprehensively evaluate the prognostic value of T1 histo-anatomic substaging (T1a/T1b) for high grade (HG) non-muscle invasive bladder cancer (NMIBC) over a large single-centre cohort.

Materials And Methods: Patients with primary HG T1 NMIBC were identified from our Institutional database, between 2011 and 2022. Data from diagnosis to repeated transurethral resection of bladder tumour (RE-TURBT), bacillus Calmette-Guérin (BCG) treatment and follow-up were collected.

View Article and Find Full Text PDF

Pyoderma gangrenosum (PG) is an extremely rare disorder in children. We report a nine-month-old girl with PG who presented with high-grade fever and rapidly progressive ulcers at the site of a Bacillus Calmette-Guérin (BCG) inoculation 2 months after the immunization. Additional small pustules developed on her hand and posterior neck three months after the immunization and rapidly progressed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!